Socioeconomic Variation and Prostate Specific Antigen Testing in the Community: A United Kingdom Based Population Study
Abstract
Purpose:
We examined the association of prostate specific antigen testing with prostate cancer incidence, tumor differentiation and mortality according to socioeconomic status.
Materials and Methods:
Participants were 96,484 men between 40 and 99 years old without preexisting prostate cancer who were registered with a general practitioner in the Tayside region of Scotland, United Kingdom, between January 1, 2003 and December 31, 2008. We performed a retrospective cohort analysis using anonymized health data, including biochemistry data on prostate specific antigen tests, Scottish Index of Multiple Deprivation, cancer registry data set and General Register Office for Scotland death records. Main outcome measures were prostate specific antigen testing, prostate cancer incidence and death.
Results:
Men in the most affluent Scottish Index of Multiple Deprivation quintile had a greater chance of undergoing a prostate specific antigen test (OR 1.48, 95% CI 1.40–1.57, p <0.001) and having prostate cancer (OR 1.48, 95% CI 1.15–1.91, p = 0.002) than men in the most deprived quintile, adjusting for age. There was no association between deprivation index quintile and prostate cancer death.
Conclusions:
Increased affluence was associated with a higher likelihood of a prostate specific antigen test and a higher incidence of prostate cancer. However, there were no observed differences by social class of the likelihood of a positive prostate specific antigen test or prostate cancer related death.
References
- 1 : International trends and patterns of prostate cancer incidence and mortality. Int J Cancer2000; 85: 60. Google Scholar
- 2 Information Services Division Scotland NHS National Services Scotland: Male Genital Organ Cancer, Prostate Cancer of the Prostate: ICD-10 C61, Annual Incidence. Available at http://www.isdscotland.org/Health-Topics/Cancer/Cancer-Statistics/Male-Genital-Organs/#prostate. Accessed December 18, 2010. Google Scholar
- 3 Information Services Division Scotland NHS National Services Scotland: Cancer in Scotland (2010). Available at http://www.isdscotland.org/Health-Topics/Cancer/Publications/2011-10-25/Cancer_in_Scotland_summary_m.pdf. Accessed December 18, 2011. Google Scholar
- 4 : Does PSA testing influence the natural history of prostate cancer?. Eur Urol, suppl.2002; 1: 3. Google Scholar
- 5 : Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol. Austria Urol2001; 58: 417. Google Scholar
- 6 : Rising incidence of prostate cancer in Scotland: increased risk or increased detection?. BJU Int2000; 85: 463. Google Scholar
- 7 Information Services Division Scotland NHS National Services Scotland: Cancer Mortality in Scotland (2010). Available at http://www.isdscotland.org/Health-Topics/Cancer/Publications/2011-10-25/2011-10-25-CancerMortality-Report.pdf?64919680357. Accessed December 18, 2011. Google Scholar
- 8 : Rates of prostate-specific antigen testing in general practice in England and Wales in asymptomatic and symptomatic patients: a cross-sectional study. BJU Int2004; 94: 51. Google Scholar
- 9 : Changing relationship between socioeconomic status and prostate cancer incidence. J Natl Cancer Inst2001; 93: 705. Google Scholar
- 10 : Socio-economic and lifestyle factors associated with the risk of prostate cancer. Br J Cancer2000; 82: 1358. Google Scholar
- 11 : Impact of socioeconomic status on prostate cancer diagnosis, treatment, and prognosis. Cancer2009; 115: 5556. Google Scholar
- 12 : Cancer patient survival by socioeconomic status in seven countries: a review for six common cancer sites. J Epidemiol Commun Health1994; 48: 441. Google Scholar
- 13 : Comparison of various characteristics of women who do and do not attend for breast cancer screening. Breast Cancer Res2002; 4: R1. Google Scholar
- 14 : PSA testing and its relationship with social deprivation. Br J Med Surg Urol2012; 5: 74. Google Scholar
- 15 Information Services Division Scotland NHS National Services Scotland: Male Genital Organ Cancer, Prostate Cancer of the Prostate: ICD-10 C61, Annual Mortality. Available at http://www.isdscotland.org/Health-Topics/Cancer/Cancer-Statistics/Male-Genital-Organs/#prostate. Accessed December 18, 2010. Google Scholar
- 16 University of Dundee: Health Informatics Centre, School of Medicine. Available at http://medicine.dundee.ac.uk/health-informatics-centre. Accessed December 18, 2012. Google Scholar
- 17 The Scottish Government: Scottish Index of Multiple Deprivation. Available at http://www.scotland.gov.uk/Topics/Statistics/SIMD. Accessed December 18, 2012. Google Scholar
- 18 :
Prostate cancer risk management programme information for primary care: PSA testing in asymptomatic men. Evidence document . In: NHS Cancer Screening Programmes. Sheffield, United Kingdom: Public Health England2010. Google Scholar - 19 : Trends in Gleason score for prostate cancer diagnosed between 1983 and 1993. J Urol2001; 165: 846. Link, Google Scholar
- 20 : Screening for prostate cancer. N Engl J Med2011; 365: 2013. Google Scholar
- 21 : Cancer surveillance series: interpreting trends in prostate cancer—part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst1999; 91: 1017. Google Scholar
- 22 : Men's knowledge and beliefs about prostate cancer: education, race, and screening status. Ethnicity Dis2009; 19: 199. Google Scholar
- 23 Hilton S: Assessment of the wider health needs of black and minority ethnic groups in Tayside. In: Revised Race Equality Scheme and Action Plan 2008-2011. NHS Tayside. Available at http://www.nhstayside.scot.nhs.uk/equality/NHS%20Tayside%20Race%20Equality%20Scheme%20-%202008-2011.pdf. Accessed December 18, 2008. Google Scholar
- 24 : Socioeconomic status and prostate cancer incidence and mortality rates among the diverse population of California. Cancer Causes Control2009; 20: 1431. Google Scholar
- 25 : Screening for prostate cancer: an updated Cochrane systematic review. BJU Int2011; 107: 882. Google Scholar
- 26 : Screening for prostate cancer remains controversial. Lancet2009; 374: 1482. Google Scholar
